Clinical efficacy of chidamide, a novel HDAC inhibitor, in relapsed/refractory NKTL patients
NKTL
DISEASE PROGRESSION
To evaluate the efficacy of chidamide, a single-arm, phase II clinical trial was performed in 28 NKTL patients who relapsed after or were refractory to chemoradiotherapy and/or autologous stem cell transplantation (ASCT). The patients were treated with chidamide until disease progression or intolerance. The demographic and clinical characteristics of the 28 patients are summarized in Additional File Efficacy of chidamide in 28 relapsed/refractory NKTL patients. 